To test or to not test: A retrospective cross-sectional study on potentially inappropriate use of pathology testing in South Australian hospitals
American Journal of Clinical Pathology · 2024
DOI: 10.1093/ajcp/aqad153 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift American Journal of Clinical Pathology, 2024. Verfasst von Twisha R Banker und 6 weiteren Autor:innen. Beteiligte Einrichtung: Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia. Hauptthemen laut MEDLINE: National Health Programs, Natriuretic Peptide, Brain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hospital Research Foundation Group.
Abstract (Originalsprache)
Objectives
To measure rates of potentially inappropriate pathology testing in the hospital setting.
Methods
Retrospective cross-sectional study in hospital setting from July 2021 to December 2021. We examined 3 potentially inappropriate uses: overordering, selection errors, and unnecessary repeat testing. Overordering included vitamin D and lipids (rarely required in acute hospital care). Selection error was the ratio of iron studies to standalone ferritin requests. Unnecessary repeats included any repeat vitamin D, lipids, iron, or ferritin in an episode of care or C-reactive protein (CRP) repeated within 3 days and N-terminal pro–brain natriuretic peptide (NT-proBNP) within 7 days and repeated previously abnormal CRP and NT-proBNP tests. Costs of inappropriate tests were estimated using the Australian Medicare Benefits Schedules.
Results
Among 55,904 test requests, 15% (n = 8120) were potentially inappropriate. Vitamin D was frequently ordered (n = 4498), as were lipids (n = 2872). Ratio of iron studies to standalone ferritin was 36. Of 19,233 repeat CRPs, 36% (n = 6947) were within 3 days and 62% (n = 179) of repeat NT-proBNPs were within 7 days of the first test. For initially abnormal tests, 89% of CRPs and 97% of NT-proBNPs remained abnormal. Inappropriate test costs accounted for 12% to 30% of costs.
Conclusions
Frequent potential inappropriate use and selection of pathology tests was observed in South Australian hospitals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
- SA Pathology, Adelaide, Australia.
- Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
- Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia.
- Discipline of Medicine, University of Adelaide, Adelaide, Australia.
ORCID-Profile: Twisha R Banker, Marianne H Gillam, Peter O'Loughlin, Wayne Rankin, Richard Ryan, Connie Caruso, Elizabeth E Roughead
Förderung
- Hospital Research Foundation Group
Zitieren
APA
Banker, T. R., Gillam, M. H., O'Loughlin, P., Rankin, W., Ryan, R., Caruso, C., & Roughead, E. E. (2024). To test or to not test: A retrospective cross-sectional study on potentially inappropriate use of pathology testing in South Australian hospitals. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqad153
Vancouver
Banker TR, Gillam MH, O'Loughlin P, Rankin W, Ryan R, Caruso C, et al. To test or to not test: A retrospective cross-sectional study on potentially inappropriate use of pathology testing in South Australian hospitals. American Journal of Clinical Pathology. 2024. doi:10.1093/ajcp/aqad153
BibTeX
@article{Banker2024,
author = {Banker, Twisha R and Gillam, Marianne H and O'Loughlin, Peter and Rankin, Wayne and Ryan, Richard and Caruso, Connie and Roughead, Elizabeth E},
title = {To test or to not test: A retrospective cross-sectional study on potentially inappropriate use of pathology testing in South Australian hospitals},
journal = {American Journal of Clinical Pathology},
year = {2024},
doi = {10.1093/ajcp/aqad153}
}
EUVIMED